Početna › Crohnova bolest › Georgia
Kliničke studije za Crohnova bolest u državi Georgia
22 studija za Crohnova bolest traži sudionike na lokacijama u državi Georgia.
Gradovi u državi Georgia
Službeni tekst studije (engleski)
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Morehouse School Of Medicine ( Site 5071), Atlanta
- Gastroenterology Associates of Central Georgia ( Site 5048), Macon
U tijeku regrutacijaFaza 3
Od 16 do 80 godina · Oba spola · Ažurirano 2. lis 2026. · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Gastroenterology Associates of Central Georgia /ID# 280464, Macon
- Gastroenterology Consultants - Roswell /ID# 281235, Roswell
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 2. lis 2026. · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Digestive Healthcare of Georgia, Atlanta
- AGA GA Research LLC, Atlanta
U tijeku regrutacijaFaza 4
Od 18 do 80 godina · Oba spola · Ažurirano 30. ruj 2026. · NCT06581328A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Emory University, Atlanta
- Children's Center for Digestive Health Care, Atlanta
U tijeku regrutacijaFaza 3
Od 2 do 17 godina · Oba spola · Ažurirano 25. ruj 2026. · NCT05923073Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Gastroenterology Associates of Central Georgia /ID# 265547, Macon
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 25. ruj 2026. · NCT06548542A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Morehouse School of Medicine, Atlanta
- Gastroenterology Associates of Central GA, Macon
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT07499232A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- Emory University, Atlanta
- Children's Center for Digestive Health Care, Atlanta
- Gastroenterolgy Associates of Central GA, Macon
U tijeku regrutacijaFaza 2/3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT07196722A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Emory University, Atlanta
- Children's Center for Digestive Healthcare, Atlanta
U tijeku regrutacijaFaza 3
Od 3 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT06663332A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- Emory University Hospital, The Emory Clinic, Atlanta
- Atlanta Center For Gastroenterology, P.C., Decatur
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 25. ruj 2026. · NCT06233461An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Atlanta Gastroenterology Associates-Site Number: 8400109, Atlanta
- M3 Wake Research - Atlanta-Site Number: 8400028, Sandy Springs
- EBGS Clinical Research Center, LLC-Site Number: 8400037, Snellville
- i još 1
U tijeku regrutacijaFaza 3
Od 16 do 80 godina · Oba spola · Ažurirano 23. ruj 2026. · NCT07184931A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- Atlanta Gastroenterology Specialists, PC, Atlanta
- Atlanta Gastroenterology Associates (Part of United Digestive), Atlanta
U tijeku regrutacijaFaza 2
Od 18 do 85 godina · Oba spola · Ažurirano 22. ruj 2026. · NCT06226883A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
- Atlanta Gastroenterology Associates - Peachtree Dunwoody, Atlanta
U tijeku regrutacijaFaza 2
Od 18 do 80 godina · Oba spola · Ažurirano 22. ruj 2026. · NCT07483073A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- Emory University School of Medicine, Atlanta
- Children's Center for Digestive Health Care, LLC, Atlanta
U tijeku regrutacijaFaza 3
Od 2 do 19 godina · Oba spola · Ažurirano 22. ruj 2026. · NCT04844606A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
- Atlanta Gastroenterology Associates - Peachtree Dunwoody, Atlanta
U tijeku regrutacijaFaza 2
Od 18 do 80 godina · Oba spola · Ažurirano 22. ruj 2026. · NCT07483099A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- Gastroenterology Consultants, P.C., Roswell
U tijeku regrutacijaFaza 4
Od 18 do 70 godina · Oba spola · Ažurirano 9. ruj 2026. · NCT06045754A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- Atlanta Gastroenterology Specialists, Suwanee
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. kol 2026. · NCT07577843A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Emory University, Atlanta
- Children's Center for Digestive Health Care, LLC, Atlanta
U tijeku regrutacijaFaza 3
Od 2 do 17 godina · Oba spola · Ažurirano 24. kol 2026. · NCT05509777Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Emory University, Atlanta
U tijeku regrutacijaFaza 4
Od 6 do 17 godina · Oba spola · Ažurirano 27. svi 2026. · NCT05781152A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Childrens Center For Digestive Healthcare, Atlanta
U tijeku regrutacijaFaza 3
Od 2 godina i više · Oba spola · Ažurirano 7. svi 2026. · NCT05442567A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- Childrens Center For Digestive Healthcare, Atlanta
U tijeku regrutacijaFaza 3
Od 2 do 17 godina · Oba spola · Ažurirano 5. svi 2026. · NCT04779320A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
- Investigational Site Number: 8400019, Marietta
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 27. ožu 2026. · NCT06958536A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Atlanta
- Mirador Therapeutics Selected Site, Snellville
U tijeku regrutacijaFaza 2
Od 18 do 80 godina · Oba spola · Ažurirano 12. ožu 2026. · NCT07113522Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.